SAN DIEGO — With the launch of their novel sustained-release CBD & THC lozenge, Pure Ratios introduces a new kind of sustained-release delivery system that rewrites how cannabis-based compounds will be administered more efficiently by mouth.
The small soft lozenge is designed to slowly dissolve in the mouth (about 30 to 45 minutes). During that time the lozenge continuously delivers a steady stream of cannabinoids to the oral mucosa. The following compositions and ratios are available: CBD 50mg & 100mg, THC Indica & Sativa 10mg & 25mg, 1:1 and 4:1 CBD/THC.
This new oral line of Pure Ratios products is based on the key realization that the oral environment offers a perfect gateway to the systemic circulation (Bloodstream), when active ingredients are delivered inside the mouth at a controlled rate and allowed to be in contact with the mucosal structures for prolonged periods of time.
“When an active is preferentially absorbed transmucosally, it enters directly into the circulation, thus creating a faster onset of action and with continued input a longer lasting effect is assured“, describes the company’s Chief Science Officer, Frank Kochinke, PhD. and adds: “By reducing the amount of active swallowed, metabolic conversion in GI tract and liver is minimized.”
While the ingredients of edibles and other conventional oral products (chewing gums, candy, cookies, tinctures, mints, sprays, etc.) are swallowed right away or washed away in minutes, the new sustained-release lozenges continuously deliver their loaded ingredients for prolonged periods of time and therefore maintain a steady active ingredient concentration gradient, the driving force for transmucosal transport. Studies demonstrate that this directly translates into a more efficient and effective delivery of a wide range of ingredients.
The company’s lozenge approach is unique in that it offers further benefits to the user by releasing additional ingredients. For example, co-delivered ingredients help to support oral hygiene by killing bacteria that cause bad breath and dry mouth or delivering ingredients that neutralize cavity-causing acids preventing tooth demineralization and plaque, etc.
The new product will be available for licensing in mid-November and will be sold through several distribution channels. Pure Ratios encourages any interested parties that will be attending the Marijuana Business Conference and Expo in Las Vegas to visit Booth 107. To arrange an appointment please contact us at firstname.lastname@example.org.
About Pure Ratios
Pure Ratios is a fast growing innovative company based in Southern California. It was founded in 2014 by William Conner, a serial entrepreneur of several successful companies. Pure Ratios offers a full line of cannabis and CBD hemp based products that we blend with essential oils and natural herbs to work synergistically together to create overall wellness for the body. The full Pure Ratios brand is available via intellectual property licensing for the production of its cannabis-infused products that target the medical and recreational markets. Our cannabis products are available in California and Arizona while our CBD hemp products are available nationally and internationally through distribution and wholesale accounts at email@example.com as well as online at www.pureratioscbd.com . For general information about the company visit www.pureratios.com.
Media Contact: Chad Conner, VP, firstname.lastname@example.org, 619-955-1339
The statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficiency of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease. All information presented here is not meant as a substitute for or alternative to information from health care practitioners. If you are taking any medication or are under treatment for any disease, please consult your health care professional about potential interactions or other possible complications before using these products. The Federal Food, Drug and Cosmetic Act requires this notice.